Solara Active Pharma Sciences · NSE: SOLARA · BSE: 541540
Q2 FY20 results · Jul–Sep 2019
Solara Active Pharma Sciences reported revenue from operations of ₹351.13 crore (up 2.6% from Q2 FY19) and net profit of ₹28.88 crore (up 237.8% from Q2 FY19) for Q2 FY20 (Jul–Sep 2019), on a consolidated basis.
| Item | Q2 FY20 | Q2 FY19 | YoY | Q1 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 351.13 | 342.33 | +2.6% | 330.17 | +6.3% |
| Other income | 4.95 | 1.39 | +256.1% | 4.36 | +13.5% |
| Total income | 356.08 | 343.72 | +3.6% | 334.53 | +6.4% |
| Profit before tax | 29.18 | 10.18 | +186.6% | 26.50 | +10.1% |
| Net profit for the period | 28.88 | 8.55 | +237.8% | 26.50 | +9.0% |
| EPS, basic (₹) | 11.21 | 3.46 | not comparable | 10.29 | not comparable |
| Net margin (%) | 8.2 | 2.5 | 8.0 |
| Item | Q2 FY20 | Q2 FY19 | YoY | Q1 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 350.36 | 336.41 | +4.1% | 314.09 | +11.5% |
| Other income | 4.41 | 0.21 | 21x | 2.97 | +48.5% |
| Total income | 354.77 | 336.62 | +5.4% | 317.06 | +11.9% |
| Profit before tax | 36.79 | 9.20 | +299.9% | 25.32 | +45.3% |
| Net profit for the period | 36.79 | 7.57 | +386.0% | 25.32 | +45.3% |
| EPS, basic (₹) | 14.27 | 1.99 | not comparable | 9.82 | not comparable |
| Net margin (%) | 10.5 | 2.3 | 8.1 |
Consolidated
- Filed with BSE
- 24 Oct 2019, 15:48 IST
- Board meeting
- 22 Oct 2019
- Period
- 01 Jul 2019 to 30 Sep 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 24 Oct 2019, 15:48 IST
- Board meeting
- 22 Oct 2019
- Period
- 01 Jul 2019 to 30 Sep 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE